Approximately 40% of human cancers exhibit alterations in the RAS-RAF-MEK-ERK signaling cascade, primarily driven by mutations in the upstream regulator RAS (around 30%) and the downstream effector BRAF (approximately 10%) [52]. Here, MAPK1 is linked to cancer.